ARRIVENT BIOPHARMA INC (AVBP) Fundamental Analysis & Valuation

NASDAQ:AVBP • US04272N1028

Current stock price

23.42 USD
+2.41 (+11.47%)
Last:

This AVBP fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. AVBP Profitability Analysis

1.1 Basic Checks

  • In the past year AVBP has reported negative net income.
  • AVBP had a negative operating cash flow in the past year.
  • AVBP had negative earnings in each of the past 5 years.
  • In the past 5 years AVBP always reported negative operating cash flow.
AVBP Yearly Net Income VS EBIT VS OCF VS FCFAVBP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 2025 -50M -100M -150M

1.2 Ratios

  • AVBP's Return On Assets of -49.92% is in line compared to the rest of the industry. AVBP outperforms 48.16% of its industry peers.
  • AVBP's Return On Equity of -54.13% is fine compared to the rest of the industry. AVBP outperforms 61.90% of its industry peers.
Industry RankSector Rank
ROA -49.92%
ROE -54.13%
ROIC N/A
ROA(3y)-40.57%
ROA(5y)-52.36%
ROE(3y)-43.73%
ROE(5y)-55.51%
ROIC(3y)N/A
ROIC(5y)N/A
AVBP Yearly ROA, ROE, ROICAVBP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 2025 -20 -40 -60 -80 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for AVBP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AVBP Yearly Profit, Operating, Gross MarginsAVBP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. AVBP Health Analysis

2.1 Basic Checks

  • AVBP has more shares outstanding than it did 1 year ago.
  • AVBP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AVBP Yearly Shares OutstandingAVBP Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 2025 10M 20M 30M 40M
AVBP Yearly Total Debt VS Total AssetsAVBP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • An Altman-Z score of 19.12 indicates that AVBP is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of AVBP (19.12) is better than 88.97% of its industry peers.
  • AVBP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 19.12
ROIC/WACCN/A
WACCN/A
AVBP Yearly LT Debt VS Equity VS FCFAVBP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 2025 0 100M -100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 12.83 indicates that AVBP has no problem at all paying its short term obligations.
  • AVBP has a better Current ratio (12.83) than 87.04% of its industry peers.
  • A Quick Ratio of 12.83 indicates that AVBP has no problem at all paying its short term obligations.
  • AVBP has a better Quick ratio (12.83) than 87.04% of its industry peers.
Industry RankSector Rank
Current Ratio 12.83
Quick Ratio 12.83
AVBP Yearly Current Assets VS Current LiabilitesAVBP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. AVBP Growth Analysis

3.1 Past

  • The earnings per share for AVBP have decreased strongly by -71.60% in the last year.
EPS 1Y (TTM)-71.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 24.37% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y11.16%
EPS Next 2Y15.94%
EPS Next 3Y24.69%
EPS Next 5Y24.37%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AVBP Yearly Revenue VS EstimatesAVBP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M
AVBP Yearly EPS VS EstimatesAVBP Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5 10

More info and screens

Find the best growth stocksShow best growing peers

1

4. AVBP Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for AVBP. In the last year negative earnings were reported.
  • Also next year AVBP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AVBP Price Earnings VS Forward Price EarningsAVBP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AVBP Per share dataAVBP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as AVBP's earnings are expected to grow with 24.69% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.94%
EPS Next 3Y24.69%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AVBP Dividend Analysis

5.1 Amount

  • No dividends for AVBP!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AVBP Fundamentals: All Metrics, Ratios and Statistics

ARRIVENT BIOPHARMA INC

NASDAQ:AVBP (3/31/2026, 12:54:42 PM)

23.42

+2.41 (+11.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-05
Earnings (Next)05-11
Inst Owners95.79%
Inst Owner Change3.35%
Ins Owners3.13%
Ins Owner Change0%
Market Cap1.04B
Revenue(TTM)N/A
Net Income(TTM)-166.31M
Analysts86.32
Price Target43.58 (86.08%)
Short Float %18.13%
Short Ratio13.9
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.33%
Min EPS beat(2)-3.09%
Max EPS beat(2)9.75%
EPS beat(4)1
Avg EPS beat(4)-49.81%
Min EPS beat(4)-180.53%
Max EPS beat(4)9.75%
EPS beat(8)5
Avg EPS beat(8)-12.2%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.79%
PT rev (3m)4.85%
EPS NQ rev (1m)2.6%
EPS NQ rev (3m)2.6%
EPS NY rev (1m)0%
EPS NY rev (3m)1.54%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)42.86%
Revenue NY rev (3m)28.57%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.37
P/tB 3.37
EV/EBITDA N/A
EPS(TTM)-4.41
EYN/A
EPS(NY)-3.92
Fwd EYN/A
FCF(TTM)-3.63
FCFYN/A
OCF(TTM)-3.63
OCFYN/A
SpS0
BVpS6.95
TBVpS6.95
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -49.92%
ROE -54.13%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-40.57%
ROA(5y)-52.36%
ROE(3y)-43.73%
ROE(5y)-55.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.83
Quick Ratio 12.83
Altman-Z 19.12
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-71.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.87%
EPS Next Y11.16%
EPS Next 2Y15.94%
EPS Next 3Y24.69%
EPS Next 5Y24.37%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-88.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2.72%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-128.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-128.72%
OCF growth 3YN/A
OCF growth 5YN/A

ARRIVENT BIOPHARMA INC / AVBP Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ARRIVENT BIOPHARMA INC?

ChartMill assigns a fundamental rating of 3 / 10 to AVBP.


What is the valuation status of ARRIVENT BIOPHARMA INC (AVBP) stock?

ChartMill assigns a valuation rating of 1 / 10 to ARRIVENT BIOPHARMA INC (AVBP). This can be considered as Overvalued.


How profitable is ARRIVENT BIOPHARMA INC (AVBP) stock?

ARRIVENT BIOPHARMA INC (AVBP) has a profitability rating of 1 / 10.


How financially healthy is ARRIVENT BIOPHARMA INC?

The financial health rating of ARRIVENT BIOPHARMA INC (AVBP) is 8 / 10.